Ivonescimab
- Generic Name
- Ivonescimab
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
本品联合培美曲塞和卡铂，用于经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06672575
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06567314
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 72
- Registration Number
- NCT06529718
- Locations
- 🇫🇷
Institute Mutualiste Montsouris, Paris, France
🇧🇪Cliniques universitaires Saint-Luc, Brussels, Belgium
🇬🇧University College London, London, United Kingdom
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 36
- Registration Number
- NCT06491472
- Locations
- 🇨🇳
Wuhan Union Hospital of China, Wuhan, China
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT06478043
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath